![]() “BioTelemetry´s technology is extremely well tailored to address the current and, importantly, future needs of payers and providers. ![]() ![]() Through the hub, the company offers cardiologists, electrophysiologists, neurologists and primary care physicians a full spectrum of cardiac monitoring solutions – ranging from extended-wear Holter monitors, event monitors, and pacemakers to its flagship mobile cardiac outpatient telemetry (MCOT) patch – unified under a single source.Īmplifying further the effect of its all-in-one platform and thanks to a network of more than 30,000 unique referring physicians per month, the BioTelemetry provides cardiac monitoring and reporting for over one million patients per year, processes over four billion heartbeats each day, and supports some of the largest clinical trials studies. In 1999, it developed a proprietary integrated patient management platform that incorporates wireless transmission of data from medical devices, FDA-cleared algorithms for processing the data, and 24-hour monitoring service centers. Since its inception, and especially since it went public in 2008 (NASDAQ:BEAT), BioTelemetry has been refining and expanding its focus on the diagnosis and monitoring of cardiac arrhythmias. It is not just an MCT player or a Holter service provider, nor is it focused on only one lever of the cardiac monitoring space – rather, its comprehensive portfolio spans devices, data management platforms, and synergistic collaborations in clinical trials. “Like all successful growth companies, we seek to augment our growth through the acquisition of other accomplished innovators whenever possible,” said Capper in the Q3 2019 earnings call last November.īioTelemetry is a mature, established player in the cardiac monitoring space with a long and rich history of innovations, acquisitions, internal pivots, and advances on multiple fronts. The secret: not just buying, but finding organizational synergies prior to each strategic purchase.Īccording to Joseph Capper, BioTelemetry's president and chief executive, the company's appetite has hardly been satisfied. While moves such as these often bring with them attendant stress, the connected health giant has more than doubled its sales and net income in the last eight years. In order to fulfil this ambitious goal, the Malvern, PA.-based company has gone on a major buying spree, acquiring nearly a dozen companies since 2012, which have put it well on its way to consolidating its power across complementary markets. did with mainframes and Intel and Microsoft did with personal computers. BioTelemetry, the leader in cardiac medical devices and remote monitoring, has been on a mission over the past decade: to dominate the space much as I.B.M.
0 Comments
Leave a Reply. |